title: A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma.
abstract: Resistance to thyroid hormone (RTH) is due to mutations in the beta-isoform of the thyroid hormone receptor (TR-beta). RTH patients display inappropriate secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyrotropin (TSH) from the anterior pituitary, despite elevated levels of thyroid hormone thyroxine (T4) and triiodothyronine (T3). Thyrotropin-secreting tumors are presumed to represent clonal expansion of abnormal cells. Because the diagnosis of TSH-secreting tumors tends to be delayed and curative surgical resection remains under 50%, early diagnosis is paramount. Current diagnostic strategies suggest that RTH patients are distinguishable from patients with TSH-secreting pituitary tumors by the use of standard laboratory tests and imaging. Here, we present a woman in whom the standard evaluation for inappropriate TSH secretion was insufficient to distinguish these entities. The patient had a low-normal TRH stimulation test and an unmeasurable alpha-glycoprotein subunit level; however, a pituitary magnetic resonance imaging (MRI) revealed an adenoma. More testing using a T3 suppression test supported a RTH diagnosis and a R438H mutation was found in the TR-beta gene. To our knowledge, this represents the first report of an apparently incidental pituitary adenoma in the setting of documented resistance to thyroid hormone. As such, it raises the question of whether RTH predisposes to pituitary hyperplasia and adenoma development.
authors.affiliation: Section of Endocrinology, Metabolism, and Diabetes, Boston University School of Medicine, Massachusetts 02118, USA. jsafer@bu.edu
authors.forename: J D
authors.initials: JD
authors.lastname: Safer
authors.forename: S D
authors.initials: SD
authors.lastname: Colan
authors.forename: L M
authors.initials: LM
authors.lastname: Fraser
authors.forename: F E
authors.initials: FE
authors.lastname: Wondisford
mesh_terms: D000236:Adenoma / Q000150:complications / Q000175:diagnosis*; D000328:Adult; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D010375:Pedigree; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis*; D017354:Point Mutation; D011388:Prolactin / Q000097:blood; D011988:Receptors, Thyroid Hormone / Q000235:genetics; D018382:Thyroid Hormone Resistance Syndrome / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone; D014284:Triiodothyronine / Q000008:administration & dosage / Q000097:blood
chemical_list: D011988:Receptors, Thyroid Hormone; D014284:Triiodothyronine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013972:Thyrotropin